Stryker's revenue growth has moderated to 7.6% year over year in 2026Q3 from 11.4% in 2025Q4, while gross margin swung between 61.3% and 68.3% over the ten reported quarters, suggesting pricing and operating leverage remain inconsistent.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has moderated to 7.6% in 2026Q3 while operating margin compressed to 15.9% from 27.3% in 2025Q4, indicating that operating income has not scaled consistently with gross profit.
Stryker Corporation has a wide moat, indicating strong competitive advantages and sustainable profitability in the medical devices sector.
The company benefits from consistent demand for medical procedures, supporting stable revenue growth.
Stryker's continued advancements in medical devices and robotics position it as a leader in healthcare technology.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $3.52-0.8% vs $3.55 | $6.5B-1.5% vs $6.6B |
Q3 2026 Jul 30, 2026 | $3.69+5.7% vs $3.49 | $6.6B+0.1% vs $6.6B |
Q2 2026 Apr 30, 2026 | $2.60-12.8% vs $2.98 | $6.0B-5.0% vs $6.3B |
Q1 2026 Jan 29, 2026 | $4.47+1.6% vs $4.40 | $7.2B+0.7% vs $7.1B |
Hospitals reorder syringes, sensors, and implants whether the economy booms or stalls, and three device makers turn that habit into payouts that grow every year.
The Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Key contributors include Microsoft, Salesforce and Thermo Fisher Scientific. Key detractors include Aon, Carrier Global and Builders FirstSource.
Boston Trust Walden Corp trimmed its stake in shares of Stryker Corporation (NYSE: SYK) by 1.2% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 289,940 shares of the medical technology company's stock after selling 3,649 shares
International Assets Investment Management LLC raised its stake in shares of Stryker Corporation (NYSE: SYK) by 1,432.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,000 shares of the medical technology company's stock after buying an
Benchmark SYK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Stryker Corporation (SYK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $325.87 | $124.93B | 34.60 | 11.16% | 13.78% | 15.61% | 1.03% | |
| $105.59 | $20.43B | 26.33 | 7.2% | 8.96% | 6.05% | 0.91% | |
| $42.75 | $63.54B | 17.79 | 19.87% | 16.56% | 13.74% | — | |
| $102.14 | $58.81B | 57.77 | 11.55% | 15.3% | 9.65% | — | |
| $211.88 | $58.38B | 50.76 | -10.91% | 5.66% | 3.67% | 1.96% | |
| $101.80 | $130.7B | 25.01 | 8.43% | 13.93% | 10.51% | 2.78% |
Stryker Corporation (SYK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Stryker Corporation (SYK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Oct 6, 2026·SEC
Jul 30, 2026·SEC
Get notified when SYK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Stryker Corporation (SYK) stock FAQ — growth, dividends, profitability & financials explained
Stryker Corporation (SYK) reported $26.30B in revenue over the trailing twelve months. Revenue was $25.12B in fiscal year 2025. That is 2660% more than the $910.1M of fiscal year 1996.
Stryker Corporation (SYK) grew revenue by 7.9% over the trailing twelve months, compared with the twelve months before.
Yes. Stryker Corporation (SYK) earned $3.62B in net income over the trailing twelve months (a 13.8% net margin).
Yes. Stryker Corporation (SYK) pays a dividend that yields 1.03% at the current price, a moderate yield.
Stryker Corporation (SYK) had a return on equity (ROE) of 15.6% over the trailing twelve months. That is above the market's typical 10-15%.
Stryker Corporation (SYK) generated $4.57B in free cash flow over the trailing twelve months.
